Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
In a recent transaction, Kim Hyong, the Chief Medical (TASE:BLWV) Officer of Alignment Healthcare, Inc. (NASDAQ:ALHC), sold 26,734 shares of common stock. The timing of this sale comes as the company’s stock has shown remarkable strength, delivering a 263% return over the past year and trading near its 52-week high of $17.76. The shares were sold at an average price of $17.2178 each, resulting in a total transaction value of approximately $460,300. Following this sale, Hyong retains ownership of 509,367 shares in the company. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which was adopted on September 5, 2024. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with 11 additional exclusive insights available to subscribers. The company’s comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks, provides detailed analysis of insider transactions and valuation metrics.
In other recent news, Alignment Healthcare reported impressive fourth-quarter 2024 earnings, surpassing analysts’ expectations with an EPS of -0.16 against a forecast of -0.18. The company’s revenue also exceeded projections, reaching $701.2 million compared to the expected $674.97 million. Piper Sandler demonstrated confidence in Alignment Healthcare by raising its price target from $14.00 to $21.00, maintaining an Overweight rating. The research firm highlighted the company’s scalable "flywheel" approach as a key driver for success. Meanwhile, Raymond (NSE:RYMD) James increased its price target for Alignment Healthcare to $19.00 and reiterated a Strong Buy rating, following the company’s robust performance in the fourth quarter. Alignment Healthcare achieved a membership growth of 59%, surpassing expectations, and reported a lower-than-expected medical loss ratio. Looking forward, the company projects 2025 revenue between $3.72 billion and $3.78 billion, with adjusted EBITDA guidance raised to $35 million to $60 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.